UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 19, 2014**

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-21846	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

8910 University Center Lane, Suite 660 **San Diego, California**	**92122**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(858) 459-7800**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

The Registrant disclosed that on Friday, September 19, 2014, it made a presentation at the 2014 Exosomes & SingleCell Analysis Summit in San Diego, California. A copy of the presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the presentation materials to its website (www.aethlonmedical.com) today, September 23, 2014.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No.	Description
99.1	Aethlon Exosome & SingleCell Analysis Summit Presentation 09-19-14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.
(Registrant)

Date: September 23, 2014

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials

Exhibit 99.1

Extracorporeal Clearance of Tumor-Secreted Exosomes; An Adjunct Strategy to Improve Cancer Treatment Outcomes

JIM JOYCE
CHAIRMAN, CEO
EXOSOMES 2014

September 18 & 19, 2014
San Diego, California

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com


We Create Targeted Therapeutic Devices to Address Infectious Disease and Cancer
aethlon
MEDICAL, INC.


2005
An Accidental Journey Into The Exosome Field
aethlon
MEDICAL, INC.


2014
THERAPEUTICS
aethlon
MEDICAL, INC.
DIAGNOSTICS
Exosome
Sciences
aethlon
MEDICAL, INC.

Exosome Sciences



A “Liquid Biopsy” Organization

aethlon MEDICAL, INC.


Exosome
Sciences
• Launched in November 2013
• Lectin-based "Liquid Biopsy" Platform
• Oncology Validations
– Bladder, Breast, Colorectal, Glioblastoma, Metastatic Melanoma, Ovarian, and Pancreatic Cancer
• Chief Scientific Officer
– Dr. Douglas Taylor
aethlon
MEDICAL, INC.

CANCER THERAPY

aethlon MEDICAL, INC.


An Adjunct Strategy to Eliminate Circulating Tumor Exosomes W/O added drug toxicity
aethlon
MEDICAL, INC.

The Aethlon Hemopurifier®

Rapid elimination of tumor-secreted exosomes

aethlon MEDICAL, INC.

Tumor-Secreted Exosomes

Extracellular Vesicles or Circulating Microvesicles



aethlon MEDICAL, INC.

aethlon MEDICAL, INC.

Tumor-Secreted Exosome Validations



aethlon MEDICAL, INC.


BREAST
MELANOMA
OVARIAN
EXOSOME
VALIDATIONS
LYMPHOMA
COLORECTAL
aethlon
MEDICAL, INC.

Why Target Tumor-Secreted Exosomes?


May, 2014
Trends in Molecular Medicine
"Extracellular Vesicles: Emerging Targets for Cancer Therapy"
THE HARVARD MEDICAL SCHOOL
NATIONAL CANCER INSTITUTE
UNIVERSITY OF OXFORD
MASSACHUSETTS GENERAL HOSPITAL
aethlon MEDICAL, INC.

Tumor-Secreted Exosomes

- Trigger apoptosis of immune cells
- Contribute to drug and chemotherapy resistance
- Promote angiogenesis
- Seed the creation and spread of metastasis
- Exosome load correlates with stage of cancer


Exosomes Transport
Biopharmaceutical Industry Targets
aethlon
MEDICAL, INC.

Programmed Cell Death 1 & Ligand (PD-1/PDL-1)

Merck: Lambrolizumab/MK-3475 (anti-PD-1 mAb)

Bristol-Myers Squibb: Nivolumab/BMS-936558 (anti-PD-1 mAb)

CureTech/Teva: Pidilizumab/CT-011 (anti-PD-1 mAb)

Roche/Genentech: MPDL3280A (anti-PD-L1 mAb)

Medimmune/AstraZeneca: MEDI4736 (anti-PD-L1 mAb)

Amplimmune/GlaxoSmithKline: AMP-224 (PD-L2-IgG1 Fc fusion protein)

CTLA-4

Bristol-Myers Squibb: Ipilimumab/Yervoy® (anti-CTLA-4 mAb)

Medimmune/Pfizer: Tremelimumab/CP-675-206 (anti-CTLA-4 mAb)

Hepatocyte growth factor (HGF) & Receptor (Met)

Amgen: Rilotumumab/AMG 102 (anti-HGF mAb)

Genentech/Roche: Onartuzumab/OA-5D (anti-Met mAb)

Aveo: Ficlatuzumab/AV-299 (anti-HGF mAb)

Amgen: AMG 337 (MET TKI)

Eli Lilly: LY-2875358 (anti-Met mAb)

ArQule: Tivantinib/ARQ 197 (MET TKI)

Novartis/Incyte: INCB28060/INC280 (MET TKI)

Fibroblast growth factor (FGF)

Novartis: Dovitinib/TK1285 (FGFR, VEGFR & PDGF TKI)

Galectin3

Galectin Therapeutics: GM-CT-01 & GR-MD-02 (galectin antagonists)

B-raf

GlaxoSmithKline: Tafinlar™/Dabrafenib (B-raf kinase inhibitor)

Genentech: Zelboraf®/Vemurafenib (B-raf kinase inhibitor)

Epidermal Growth Factor Receptor (EGFR)

Genentech: Tarceva®/Erlotinib (EGFR TKI)

Bristol-Myers Squibb & Eli Lilly: Cetuximab/Erbitux (anti-EGFR mAb)

Amgen: Vectitbix/Panitumumab (anti-EGFR mAb)

Boehringer Ingelheim: Gilotrif™/Afatinib (EGFR/HER2 TKI)

HER2

Genentech: Herceptin®/Trastuzumab (anti-HER2 mAb)

Genentech: Kadcyla®/Ado-trastuzumab emtansine (anti-HER2 mAb linked to DM1 drug)

Genentech: Perjeta®/Pertuzimab (anti-HER2 mAb)

GlaxoSmithKline: Tykerb/Lapatinib (dual TKI against HER2 and EGFR)

CD20

Biogen Idec & Genentech: Rituxan®/Rituximab (anti-CD20 mAb)

GlaxoSmithKline: Arzerra™/Ofatumumab (anti-CD20 mAb)

Genentech: Gazyva™/Obinutuzumab (anti-CD20 mAb)

P-glycoprotein

Novartis: Valspodar/PSC-833 (P-glycoprotein inhibitor).

Vascular endothelial growth factor (VEGF) & Receptor (VEGFR)

Genentech/Roche: Avastin®/Bevacizumab (anti-VEGF mAb)

Eli Lilly: Cyramza™ /Ramucirumab (anti-VEGFR2 mAb)

Exelixis/GlaxoSmithKline: Foretnib/XL880/GSK1363089 (MET/VEGFR2 inhibitor)

Sanofi & Regeneron: Zaltrap®/Ziv-Afibercept (VEGFR1/2 IgG1 Fc fusion protein)


Will the Elimination of Circulating Tumor-Secreted Exosomes Improve Outcomes?
aethlon
MEDICAL, INC.

BY THE WAY!

The Aethlon Hemopurifier®

aethlon MEDICAL, INC.

Hemopurifier® Therapy

- FDA approved IDE to initiate U.S. studies
- Administered in ~100 human treatment experiences
  - HIV and Hepatitis C (HCV) Infected Individuals
  - Broad-spectrum *in vitro* data against category "A" bioterror and pandemic threats, including ebola

The Aethlon Hemopurifier®

Currently Preparing Submission of Cancer IDE

aethlon MEDICAL, INC.


Does the Elimination of Circulating Tumor-Secreted Exosomes Improve Outcomes?
aethlon
MEDICAL, INC.


We Create Targeted Therapeutic Devices to Address Infectious Disease and Cancer
aethlon
MEDICAL, INC.


Save Lives
aethlon
MEDICAL, INC.